Ten patients with metastatic prostatic cancer no longer responsive to conventional doses of
estrogens (stilbestrol 15 mg. daily or equivalent) were treated with high doses of …

METHOD Sixty-six patients with proven prostatic carcinoma have been given this
compound. Thirty-four of these had failed to respond or had become refractory to the usual …

METHOD For ease in interpretation of results, identical dosage was administered to each
patient over a standard period of time, regardless of changes in symptomatology or in acid …

Diethylstilbestrol diphosphate (DES-P) has shown effective symptomatic relief in patients
with metastatic carcinoma of the prostate. Although there is little known about its role in soft …

The patient presenting with severe bone pain after primary hormonal therapy, with vertebral
collapse, or with uremia resulting from ureteric obstruction should be considered for …

Since Huggins stimulated interest in hormonal control of prostatic cancer, advance has been
hampered by gaps in our basic knowledge of living cell physiopathology. For no evident …

Experience of recent years has proved that hormone treatment of carcinoma of the prostate,
although valuable, should be regarded as palliative only. Attempts have been made to …

Cyproterone acetate is a steroidal antiandrogen with weak progestational activity that results
in the partial suppression of pituitary gonadotropin. We demonstrate that the associated …

Abstract Twenty patients (16 Stage D, 4 Stage C) with prostatic cancer were treated with
megestrol acetate (Megace), 160 mg. daily. Of 9 previously untreated patients, 4 had partial …

Data are drawn from the pertinent literature supporting diethylstilbestrol for initial endocrine
treatment of advanced prostatic cancer. When diethylstilbestrol is given in a dosage of 2 mg …